FIELD: chemical industry. SUBSTANCE: hydroxamic acid derivatives of general formula given in the specification in which m=0 and 2; x is halogen; R is phenyl which is substituted by (CI- C4) alkoxy, or pyridyl; R1 is hydrogen of (CI-C5)-alkyl; R2 is (CI- C5) alkyl, (C5-C7) cycloalkyl or R1 and R2 taken together with nitrogen atom to which they are attached form heterocyclic radical, and acid addition salts thereof are prepared either by treatment of compound of general formula VII given in the specification, wherein R1- R2 are as defined above, with halogenaling agent followed by hydrolysis in aqueous alkaline medium and recovery of the desired product in the form of base or acid addition salt, or by diazotization of compound of general formula (II) given in the specification followed by decomposition of the resulting diazonium salt and recovery of the desired product in the form of base ar acid addition salt. EFFECT: more efficient preparation methods. 4 cl
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVE OF PYRIDINE-1-OXIDE AND METHODS FOR ITS CONVERSION TO PHARMACEUTICALLY EFFECTIVE COMPOUNDS | 2001 |
|
RU2281282C2 |
ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE DERIVATIVES OF AROMATICS, PHARMACEUTICAL COMPOSITION BASED ON THEM AND WAY OF TREATMENT AGAINST ABNORMALITIES RESPONSIVE TO DOPAMINE D RECEPTOR LIGAND TREATMENT, WITH THEIR HELP | 2005 |
|
RU2442781C2 |
METHOD OF TREATMENT OR PREVENTION OF PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS MEDIATED BY GROWTH HORMONE SECRETION STIMULATING RECEPTORS, TRIAZOLE AND BASED PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2415134C9 |
SUBSTITUTED 3-OXO-1,2,3,4-TETRAHYDROXINOXALINES, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHODS FOR PRODUCTION AND USES THEREOF | 2003 |
|
RU2251546C1 |
METHOD OF OBTAINING DISPIROINDOLINONES | 2018 |
|
RU2682678C1 |
METHOD FOR IMPROVEMENT OF STABILITY OF SWEET TASTE INTENSIFIERS AND COMPOSITION CONTAINING STABILISED SWEET TASTE INTENSIFIER | 2011 |
|
RU2576451C2 |
DERIVATIVES OF ANDROSTANE SUBSTITUTED AT 16-POSITION WITH QUATERNARY AMMONIUM GROUP, PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2124021C1 |
N-(1H-IMIDAZOL-2-YL)BENZAMIDE AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS ACTIVE INGREDIENT | 2020 |
|
RU2806754C1 |
GCN2 INHIBITORS AND THEIR USE | 2019 |
|
RU2811408C2 |
BETA-LACTAMASE INHIBITORS AND THEIR USE | 2018 |
|
RU2815314C2 |
Authors
Dates
1997-10-20—Published
1989-10-19—Filed